Skip to main content
SpringerLink
Log in

Safety Parameters and Risk Categories Used for Psychotropic Drugs in Pregnancy and Lactation

  • Chapter
  • First Online:
Perinatal Psychopharmacology

  • 944 Accesses

Abstract

Pharmacotherapy is frequently required for pregnant and breastfeeding women with psychiatric illness. This chapter aims to review the basic principles for assessing medication use during pregnancy and lactation in order to help clinical decision-making. The concepts are exemplified by psychotropic drugs, in case the information is available. An update on recent changes in the FDA pregnancy risk categories is also provided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Källén B. Drugs in pregnancy - the dilemma of labeling. Drug Inf J. 1999;33:1135–43.

    Article  Google Scholar 

  2. Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf. 2000;23(3):245–53.

    Article  CAS  Google Scholar 

  3. Dunlop AL, Jack BW, Bottalico JN, Lu MC, James A, Shellhaas CS, Hallstrom LH, Solomon BD, Feero WG, Menard MK, Prasad MR. The clinical content of preconception care: women with chronic medical conditions. Am J Obstet Gynecol. 2008;199(6 Suppl 2):S310–27.

    Article  Google Scholar 

  4. Chatterjee S, Kotelchuck M, Sambamoorthi U. Prevalence of chronic illness in pregnancy, access to care, and health care costs: implications for interconception care. Womens Health Issues. 2008;18(6 Suppl):S107–16.

    Article  Google Scholar 

  5. Kersten I, Lange AE, Haas JP, Fusch C, Lode H, Hoffmann W, Thyrian JR. Chronic diseases in pregnant women: prevalence and birth outcomes based on the SNiP-study. BMC Pregnancy Childbirth. 2014;14:75.

    Article  Google Scholar 

  6. Feibus KB. FDA’s proposed rule for pregnancy and lactation labeling: improving maternal child health through well-informed medicine use. J Med Toxicol. 2008;4:284–8.

    Article  Google Scholar 

  7. Frederiksen MC. The new FDA pregnancy labeling requirements for drugs. J Midwifery Womens Health. 2011;56:303–7.

    Article  Google Scholar 

  8. Sahin L, Nallani SC, Tassinari MS. Medication use in pregnancy and the pregnancy and lactation labeling rule. Clin Pharmacol Ther. 2016;100(1):23–5.

    Article  CAS  Google Scholar 

  9. Brent RL. Utilization of animal studies to determine the effects and human risks of environmental toxicants (drugs, chemicals, and physical agents). Pediatrics. 2004a;113(4 Suppl):984–95.

    PubMed  Google Scholar 

  10. Grigoriadis S, Vonderporten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014;348:f6932.

    Article  Google Scholar 

  11. Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs. 2008;22:325–234.

    Article  CAS  Google Scholar 

  12. Kaneko S, Battino D, Andermann E, Wada K, Kan R, Takeda A, Nakane Y, Ogawa Y, Avanzini G, Fumarola C, Granata T, Molteni F, Pardi G, Minotti L, Canger R, Dansky L, Oguni M, Lopes-Cendas I, Sherwin A, Andermann F, Seni MH, Okada M, Teranishi T. Congenital malformations due to antiepileptic drugs. Epilepsy Res. 1999;33(2-3):145–58.

    Article  CAS  Google Scholar 

  13. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F, EURAP Study Group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–17.

    Article  CAS  Google Scholar 

  14. Bromley RL, Mawer G, Love J, Kelly J, Purdy L, McEwan L, Briggs M, Clayton-Smith J, Shi X, Baker GA. Liverpool and Manchester Neurodevelopment Group (LMNDG): Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia. 2010;51:2058–65.

    Article  Google Scholar 

  15. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW. NEAD Study Group: Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009;360:1597–605.

    Article  CAS  Google Scholar 

  16. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Curry CJ, Fernhoff PM, Grix AW Jr, Lott IT, Richard JM, Sun SC. Retinoic acid embryopathy. N Engl J Med. 1985;313(14):837–41.

    Article  CAS  Google Scholar 

  17. Camera G, Pregliasco P. Ear malformation in baby born to mother using tretinoin cream. Lancet. 1992;339(8794):687.

    Article  CAS  Google Scholar 

  18. Lipson AH, Collins F, Webster WS. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet. 1993;341(8856):1352–3.

    Article  CAS  Google Scholar 

  19. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993;341(8854):1181–2.

    Article  CAS  Google Scholar 

  20. Loureiro KD, Kao KK, Jones KL, Alvarado S, Chavez C, Dick L, Felix R, Johnson D, Chambers CD. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A. 2005;136(2):117–21.

    Article  Google Scholar 

  21. Panchaud A, Csajka C, Merlob P, Schaefer C, Berlin M, De Santis M, Vial T, Ieri A, Malm H, Eleftheriou G, Stahl B, Rousso P, Winterfeld U, Rothuizen LE, Buclin T. Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study. J Clin Pharmacol. 2012;52(12):1844–51.

    Article  CAS  Google Scholar 

  22. Shapiro L, Pastuszak A, Curto G, Karen G. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet. 1997;350(9085):1143–4.

    Article  CAS  Google Scholar 

  23. Kaplan YC, Ozsarfati J, Etwel F, Nickel C, Nulman I, Koren G. Pregnancy outcomes following first trimester exposure to topical retinoids: a systematic review and meta-analysis. Br J Dermatol. 2015b;173(5):1132–41.

    Article  CAS  Google Scholar 

  24. Jensen BK, McGann LA, Kachevsky V, Franz TJ. The negligible systemic availability of retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris. J Am Acad Dermatol. 1991;24:425–8.

    Article  CAS  Google Scholar 

  25. Lehman PA, Slattery JT, Franz TJ. Percutaneous absorption of retinoids: influence of vehicle, light exposure, and dose. J Invest Dermatol. 1988;91:56–61.

    Article  CAS  Google Scholar 

  26. Sadowski A, Todorow M, Yazdani Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open. 2013;3(7):pii: e003062.

    Article  Google Scholar 

  27. Vajda FJ. The Australian pregnancy register of antiepileptic drugs: 10 years of progress. J Clin Neurosci. 2010;17:1485–8.

    Article  CAS  Google Scholar 

  28. Vajda FJ, Hitchcock AA, Graham J, O’Brien TJ, Lander CM, Eadie MJ. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia. 2010;51:805–10.

    Article  CAS  Google Scholar 

  29. Vajda FJ, O’Brien TJ, Lander CM, Graham J, Eadie MJ. Antiepileptic drug combinations not involving valproate and the risk of fetal malformations. Epilepsia. 2016;57(7):1048–52.

    Article  CAS  Google Scholar 

  30. Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011;157(3):175–82.

    Article  Google Scholar 

  31. Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol. 2002;100(3):465–73.

    CAS  PubMed  Google Scholar 

  32. Brent RL. Environmental causes of human congenital malformations: the pediatrician’s role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics. 2004b;113(4 Suppl):957–68.

    PubMed  Google Scholar 

  33. Guittina P, Eléfant E, Saint-Salvi B. Hierarchization of animal teratology findings for improving the human risk evaluation of drugs. Reprod Toxicol. 2000;14:369–75.

    Article  CAS  Google Scholar 

  34. Shepard TH. Proof of human teratogenicity. Teratology. 1994;50:97–8.

    Article  CAS  Google Scholar 

  35. Carey JC, Martinez L, Balken E, Leen-Mitchell M, Robertson J. Determination of human teratogenicity by the astute clinician method: review of illustrative agents and a proposal of guidelines. Birth Defects Res A Clin Mol Teratol. 2009;85(1):63–8.

    Article  CAS  Google Scholar 

  36. Fourie DT, Hay IT. Warfarin as a possible teratogen. S Afr Med J. 1975;49(50):2081–3.

    CAS  PubMed  Google Scholar 

  37. Holzgreve W, Carey JC, Hall BD. Warfarin-induced fetal abnormalities. Lancet. 1976;2(7991):914–5.

    Article  CAS  Google Scholar 

  38. Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescence: a report of 7 cases including 6 clear-cell carcinomas. Cancer. 1970;25:745–57.

    Article  CAS  Google Scholar 

  39. Rosa FW. Teratogenicity of isotretinoin. Lancet. 1983;2:513.

    Article  CAS  Google Scholar 

  40. Lee BE, Feinberg M, Abraham JJ, Murthy AR. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J. 1992;11(12):1062–4.

    Article  CAS  Google Scholar 

  41. Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley J. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis. 1996;22(2):336–40.

    Article  CAS  Google Scholar 

  42. Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol. 2004;103(5 Pt 2):1091–4.

    Article  Google Scholar 

  43. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82(12):1698–7102.

    Article  CAS  Google Scholar 

  44. Song F, Hooper L, Loke YK. Publication bias: what is it? How do we measure it? How do we avoid it. Open Access J Clin Trials. 2013;5(1):51–81.

    Google Scholar 

  45. Leen-Mitchell M, Martinez L, Gallegos S, Robertson J, Carey JC. Mini-review: history of organized teratology information services in North America. Teratology. 2000;61:314–7.

    Article  CAS  Google Scholar 

  46. Schaefer C. Drug safety in pregnancy: utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information Services. Congenit Anom (Kyoto). 2011;51:6–11.

    Article  Google Scholar 

  47. Irl C, Hasford J. Assessing the safety of drugs in pregnancy: the role of prospective cohort studies. Drug Saf. 2000;22(3):169–77.

    Article  CAS  Google Scholar 

  48. Källén B. The problem of confounding in studies of the effect of maternal drug use on pregnancy outcome. Obstet Gynecol Int. 2012;2012:148616.

    Article  Google Scholar 

  49. Ehrenstein V, Sørensen HT, Bakketeig LS, Pedersen L. Medical databases in studies of drug teratogenicity: methodological issues. Clin Epidemiol. 2010;2:37–43.

    Article  Google Scholar 

  50. Mitchell AA. Systematic identification of drugs that cause birth defects - a new opportunity. N Engl J Med. 2003;349(26):2556–9.

    Article  CAS  Google Scholar 

  51. Egger M, Ebrahim S, Smith GD. Where now for meta-analysis? Int J Epidemiol. 2002;31(1):1–5.

    Article  Google Scholar 

  52. Chambers C. The role of teratology information services in screening for teratogenic exposures: challenges and opportunities. Am J Med Genet C Semin Med Genet. 2011;157C(3):195–200.

    Article  Google Scholar 

  53. Nulman I, Koren G, Rovet J, Barrera M, Streiner DL, Feldman BM. Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling study. J Clin Psychiatry. 2015;76(7):e842–7.

    Article  Google Scholar 

  54. Bateman BT, Huybrechts KF, Fischer MA, Seely EW, Ecker JL, Oberg AS, Franklin JM, Mogun H, Hernandez-Diaz S. Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. Am J Obstet Gynecol. 2015;212(3):337.e1–14.

    Article  Google Scholar 

  55. Correa A, Gilboa SM, Besser LM, Botto LD, Moore CA, Hobbs CA, Cleves MA, Riehle-Colarusso TJ, Waller DK, Reece EA. Diabetes mellitus and birth defects. Am J Obstet Gynecol. 2008;199:237.e1–9.

    Article  Google Scholar 

  56. Källén BA. Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenit Anom (Kyoto). 2005;45(2):44–51.

    Article  Google Scholar 

  57. Koren G, Madjunkova S, Maltepe C. Bias against the null hypothesis: scaring pregnant women about drugs in pregnancy. Can Fam Physician. 2014;60(5):441–2.

    PubMed  PubMed Central  Google Scholar 

  58. Larsen ER, Damkier P, Pedersen LH, Fenger-Gron J, Mikkelsen RL, Nielsen RE, Linde VJ, Knudsen HE, Skaarup L, Videbech P, Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1–28.

    Article  CAS  Google Scholar 

  59. EMEA. Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling. London: European Medicines Agency; 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003307.pdf. Accessed on 12 Feb 2018.

    Google Scholar 

  60. Drugs and Lactation Database (LactMed). Toxnet. Bathesda, MD: National Institutes of Health; 2018. https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm. Accessed on 12 Feb 2018.

    Google Scholar 

  61. Hotham N, Hotham E. Drugs in breastfeeding. Aust Prescr. 2015;38:156–9.

    Article  Google Scholar 

  62. Hale TW. Medications and mothers’ milk. 15th ed. Amarillo, TX: Hale Publishing; 2012.

    Google Scholar 

  63. Ilett KF, Kristensen JH. Drug use and breastfeeding. Expert Opin Drug Saf. 2005;4:745–68.

    Article  CAS  Google Scholar 

  64. Madadi P, Avard D, Koren G. Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. Curr Drug Metab. 2012;13(6):721–7.

    Article  CAS  Google Scholar 

  65. Sistonen J, Madadi P, Ross CJ, et al. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther. 2012;91(4):692–9.

    Article  CAS  Google Scholar 

  66. Hale TW, Rowe HE. Medications and mothers milk. 17th ed. New York, NY: Springer Publishing Company; 2017.

    Google Scholar 

  67. Anderson PO, Manoguerra AS, Valdés V. A review of adverse reactions in infants from medications in breastmilk. Clin Pediatr (Phila). 2016;55(3):236–44.

    Article  Google Scholar 

  68. Richards JS, Williams JJ. Luteal cell receptor content for prolactin (PRL) and luteinizing hormone (LH): regulation by LH and PRL. Endocrinology. 1976;99:1571–81.

    Article  CAS  Google Scholar 

  69. Ito S. Chronic illness and the breastfeeding mother. J Popul Ther Clin Pharmacol. 2014;21(3):e565–8.

    PubMed  Google Scholar 

  70. Kaplan YC, Koren G, Ito S, Bozzo P. Fluconazole use during breastfeeding. Can Fam Physician. 2015a;61(10):875–6.

    PubMed  PubMed Central  Google Scholar 

  71. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42–52.

    Article  CAS  Google Scholar 

  72. Sachs HC. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013;132:e796–809.

    Article  Google Scholar 

  73. Amir LH, Pirotta MV. Medicines for breastfeeding women: a postal survey of general practitioners in Victoria. Med J Aust. 2009;191(2):126.

    PubMed  Google Scholar 

  74. Holmes LB. Human teratogens: update 2010. Birth Defects Res A Clin Mol Teratol. 2011;91:1–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Faculty of Medicine, Izmir Katip Celebi University, Izmir, Turkey

    Yusuf Cem Kaplan & Hilal Erol-Coskun

  2. Teratology Information, Research and Training Center, Terafar-Izmir Katip Celebi University, Izmir, Turkey

    Yusuf Cem Kaplan & Hilal Erol-Coskun

Authors
  1. Yusuf Cem Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hilal Erol-Coskun
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey

    Faruk Uguz

  2. Psychopharmacological, Drug Misuse and Novel Psychoactive Substances Research Unit, University of Hertfordshire, Hatfield, UK

    Laura Orsolini

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kaplan, Y.C., Erol-Coskun, H. (2019). Safety Parameters and Risk Categories Used for Psychotropic Drugs in Pregnancy and Lactation. In: Uguz, F., Orsolini, L. (eds) Perinatal Psychopharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-92919-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92919-4_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92918-7

  • Online ISBN: 978-3-319-92919-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation